液体活检技术在前列腺癌中的应用及研究进展

林智谦; 王世博; 梁英; 田俊强

doi:10.13201/j.issn.1001-1420.2019.02.017

液体活检技术在前列腺癌中的应用及研究进展

- 兰州大学第二医院泌尿外科兰州大学第二医院泌尿外科研究所甘肃省泌尿系统疾病重点实验室甘肃省泌尿系统疾病临床医学中心(兰州, 730030)
基金项目:
甘肃省卫生行业科研计划项目(编号GWGL2013-30)

兰州大学第二医院2015年度第二批院内博士科研基(编号ynbskyjj2015-2-7)

详细信息

通讯作者: 田俊强,E-mail:tjq007263@sina.com

中图分类号: R737.25

收稿日期: 2017-09-12

Progress and application of liquid biopsy in prostatic cancer

- Department of Urology, Second Hospital of Lanzhou University, Institute of Urology of Second Hospital of Lanzhou University Key Laboratory for Urological Diseases of Gansu Province, Gansu Nephro Urological Clinical Center, Lanzhou, 730030, China

More Information

Corresponding author: TIAN Junqiang, E-mail: tjq007263@sina.com

Received Date: 12 September 2017

摘要

摘要: 液体活检技术是通过对癌症患者体液(特别是血液和尿液)中的特异性肿瘤标志物如循环肿瘤细胞(CTCs)、循环肿瘤DNA等进行检测并分析,其对肿瘤的临床分期、远处转移、预后判断、耐药性的形成机制以及个体化治疗指导都具有深远意义。前列腺癌早期诊断较为困难,而且部分病例恶性程度高,易复发和转移。近几年来,该技术已经应用在前列腺癌诊治中并积累了许多非常有价值的临床数据和经验。本文对液体活检技术在前列腺癌中的研究现状及面临的挑战作一综述。
- 液体活检技术 /
- 循环肿瘤细胞 /
- 循环肿瘤DNA /
- 前列腺癌
Abstract: Liquid biopsy is a popular technology to detect and analyze specific tumor biomarkers (such as circulating tumor cells, circulating tumor DNA, etc.) in the body fluids (especially blood and urine) of cancer patients.It plays a key role in clinical tumor staging, metastasis, prognosis, drug resistance research and individualized treatment.It is well known that early diagnosis of prostate cancer is a little difficult, and part of patients show high malignancy and incidence of recurrence and metastasis.In recent years, this technology has been used in the diagnosis and treatment of prostate cancer and accumulated a lot of very valuable clinical data and experience.This review summarized recent literature and briefly discussed the current status and challenges of liquid biopsy in prostate cancer.
- liquid biopsy technology /
- circulating tumor cells /
- circulating tumor DNA /
- prostatic cancer

HTML全文

参考文献(28)

[1]	Richman D M, Tirumani S H, Hornick J L, et al.Beyond gastric adenocarcinoma:Multimodality assessment of common and uncommon gastric neoplasms[J].Abdom Radiol (NY), 2017, 42 (1): 124-140.
[2]	Chen W, Zheng R, Baade P D, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2): 115-132.
[3]	Masuda T, Hayashi N, Iguchi T, et al.Clinical and biological significance of circulating tumor cells in cancer[J].Mol Oncol, 2016, 10 (3): 408-417.
[4]	谢建湖, 潘宏信, 李伟东.前列腺癌循环肿瘤细胞的检测及其临床应用的研究进展[J].临床泌尿外科杂志, 2016, 31 (7): 674-678.
[5]	King M R, Phillips K G, Mitrugno A, et al.A physical sciences network characterization of circulating tumor cell aggregate transport[J].Am J Physiol Cell Physiol, 2015, 308 (10): C792-C802.
[6]	Cooke N M, Spillane C D, Sheils O, et al.Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion[J].BMC Cancer, 2015, 15:627.
[7]	Lianidou E S, Strati A, Markou A.Circulating tumor cells as promising novel biomarkers in solid cancers[J].Crit Rev Clin Lab Sci, 2014, 51 (3): 160-171.
[8]	Huang T, Jia C P, Jun-Yang, et al.Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip[J].Biosens Bioelectron, 2014, 51:213-218.
[9]	Hosokawa M, Kenmotsu H, Koh Y, et al.Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system[J].PLoS One, 2013, 8 (6): e67466.
[10]	Nurwidya F, Zaini J, Putra A C, et al.Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer[J].Chonnam Med J, 2016, 52 (3): 151-158.
[11]	Lack J, Gillard M, Cam M, et al.Circulating tumor cells capture disease evolution in advanced prostate cancer[J].J Transl Med, 2017, 15 (1): 44.
[12]	Onstenk W, Sieuwerts A M, Kraan J, et al.Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells[J].Eur Urol, 2015, 68 (6): 939-945.
[13]	Antonarakis E S, Lu C, Luber B, et al.Androgen Receptor Splice Variant 7and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer[J].JAMA Oncol, 2015, 1 (5): 582-591.
[14]	Taneja S S.Re:Androgen Receptor Splice Variant 7and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer[J].JUrol, 2016, 195 (5): 1472-1473.
[15]	Gupta S, Li J, Kemeny G, et al.Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer[J].Clin Cancer Res, 2017, 23 (5): 1346-1357.
[16]	Meyer C P, Pantel K, Tennstedt P, et al.Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer[J].Urol Oncol, 2016, 34 (5): 235e11-235e16.
[17]	Kolostova K, Broul M, Schraml J, et al.Circulating tumor cells in localized prostate cancer:isolation, cultivation in vitro and relationship to T-stage and Gleason score[J].Anticancer Res, 2014, 34 (7): 3641-3646.
[18]	Josefsson A, Linder A, Flondell Site D, et al.Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naive Prostate Cancer[J].Prostate, 2017, 77 (8): 849-858.
[19]	Lorente D, Olmos D, Mateo J, et al.Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer[J].Eur Urol, 2016, 70 (6): 985-992. (上接第156页)
[20]	Antonarakis E S, Lu C, Luber B, et al.Clinical Significance of Androgen Receptor Splice Variant-7 mRNADetection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First-and Second-Line Abiraterone and Enzalutamide[J].J Clin Oncol, 2017, 35 (19): 2149-2156.
[21]	Leibrand C R, Price D K, Figg W D.Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castrationresistant prostate cancer:Biomarker for treatment selection exclusion or inclusion?[J].Cancer Biol Ther, 2016, 17 (5): 467-469.
[22]	Delgado P O, Alves B C, Gehrkefde S, et al.Characterization of cell-free circulating DNA in plasma in patients with prostate cancer[J].Tumour Biol, 2013, 34 (2): 983-986.
[23]	Ulivi P, Silvestrini R.Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer[J].Cell Oncol (Dordr), 2013, 36 (6): 439-448.
[24]	Bratman S V, Newman A M, Alizadeh A A, et al.Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq[J].Expert Rev Mol Diagn, 2015, 15 (6): 715-719.
[25]	Krebs M G, Metcalf R L, Carter L, et al.Molecular analysis of circulating tumour cells-biology and biomarkers[J].Nat Rev Clin Oncol, 2014, 11 (3): 129-144.
[26]	Gordian E, Ramachandran K, Reis I M, et al.Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease[J].Cancer Epidemiol Biomarkers Prev, 2010, 19 (8): 1984-1991.
[27]	Helzer K T, Barnes H E, Day L, et al.Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model[J].Cancer Res, 2009, 69 (19): 7860-7866.
[28]	丁辉, 吴振启.核酸检测在前列腺癌诊断中的研究现状[J].临床泌尿外科杂志, 2016, 31 (9): 857-861.